Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Ribosomal protein L23a pseudogene 19 (RPL23AP19)** is a human processed pseudogene related to the RPL23A gene, which encodes a component of the large 60S ribosomal subunit involved in protein synthesis[4]. Like most ribosomal protein pseudogenes, RPL23AP19 is a non-functional genomic sequence that shares high sequence similarity with its parental gene but does not code for a functional protein[3][4]. These pseudogenes are numerous in the human genome, and while some ribosomal protein pseudogenes have been studied for potential regulatory roles, there is no evidence that RPL23AP19 serves a therapeutic, biomarker, or functional role in health or disease. It is not considered a drug target, nor does it encode a receptor, enzyme, transporter, or signaling molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 19 (RPL23AP19).